Table 1.
Incidence, latency, and spectrum of lymphomas induced by the MyrAkt and AktE40K transgenes
| Line | No. of mice | Deaths | Thymomas | Thymomas and splenomegaly | Splenomegaly | Not det* | Age of animals at time of death, days |
|---|---|---|---|---|---|---|---|
| MyrAkt (founders) | 21 | 15 | 7 | 3 | 1 | 4 | 146.6 ± 131.0 |
| MyrAkt (M-1) | 43 | 40 | 21 | 10 | 0 | 9 | 127.8 ± 77.0 |
| MyrAkt (M-9) | 22 | 19 | 6 | 10 | 2 | 1 | 193.0 ± 97.8 |
| MyrAkt (M-24) | 4 | 4 | 4 | 0 | 0 | 0 | 66.5 ± 0.9 |
| AktE40K (founders) | 18 | 3 | 1 | 0 | 1 | 1 | 525.7 ± 165.3 |
| AktE40K (E-3) | 55 | 33 | 5 | 8 | 6 | 13 | 264.0 ± 117.3 |
| AktE40K (E-4) | 27 | 11 | 0 | 3 | 5 | 3 | 297.3 ± 119.5 |
| Nontransgenic | 30 | 6 | 0 | 0 | 2 | 4 | 499.5 ± 133.3 |
Mice were monitored for a total of 600 days. Ages are mean ± SD.
*
This column includes mice that were discovered dead, and because of autolysis the cause of their death could not be determined objectively.